A study for adults with severe alopecia areata comparing amlitelimab (subcutaneous injections) to placebo
Recruiting
18 years or above
All
Phase
2
150 participants needed
1 Location
Aperçu de l'étude
Test ETL
Détails de l'étude
This study will include approximately 150 participants in 16 countries.
All participants will have a 2 out of 3 chance of receiving the investigational medication (or 1 out of 3 chance of receiving the placebo). A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. This study is a double blinded study, meaning neither the participants nor the study doctors know who is given the investigational medicine or the placebo.
The study will last a little over a year (56 weeks) and include 12 visits to the study center. During the study you will receive nine (9) injections just under the skin of your abdomen, thigh or upper arm. Participants may have the possibility to continue treatment with the investigational medication following this study. Study assessments include:
- Physical exam
- Electrocardiogram (ECG)
- Blood and urine tests
- Clinician and patient reported outcomes (questionnaires)
There is no cost to participate. All study-related exams, study-related medications and study-related medical care is provided. There is no insurance required to take part in this study. You may be compensated for time and travel.
Critère d'éligibilité
You may be eligible for this study if you meet the following criteria:
- Conditions: Alopecia Areata
-
Age: 18 years or above
-
Gender: All
Updated on
03 Dec 2024.
Study ID: NCT06444451